BDNF and cortisol in the diagnosis of cocaine-induced depression

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Fonseca Casals, Francina, 1972-
  • dc.contributor.author Mestre-Pintó, Juan Ignacio
  • dc.contributor.author Rodríguez-Minguela, Rocío
  • dc.contributor.author Papaseit Fontanet, Esther
  • dc.contributor.author Pérez Mañá, Clara
  • dc.contributor.author Langohr, Klaus
  • dc.contributor.author Barbuti, Margherita
  • dc.contributor.author Farré Albaladejo, Magí
  • dc.contributor.author Torrens, Marta
  • dc.contributor.author Neurodep Group
  • dc.date.accessioned 2022-09-20T06:05:22Z
  • dc.date.available 2022-09-20T06:05:22Z
  • dc.date.issued 2022
  • dc.description.abstract Background: Major depressive disorder (MDD) and cocaine use disorder (CUD) are related with disability and high mortality rates. The assessment and treatment of psychiatric comorbidity is challenging due to its high prevalence and its clinical severity, mostly due to suicide rates and the presence of medical comorbidities. The aim of this study is to investigate differences in brain derived neurotrophic factor (BDNF) and cortisol plasmatic levels in patients diagnosed with CUD-primary-MDD and CUD-induced-MDD and also to compare them to a sample of MDD patients (without cocaine use), a sample of CUD (without MDD), and a group of healthy controls (HC) after a stress challenge. Methods: A total of 46 subjects were included: MDD (n = 6), CUD (n = 15), CUD-primary-MDD (n = 16), CUD-induced-MDD (n = 9), and 21 HC. Psychiatric comorbidity was assessed with the Spanish version of the Psychiatric Research Interview for Substance and Mental Disorders IV (PRISM-IV), and depression severity was measured with the Hamilton Depression Rating Scale (HDRS). Patients were administered the Trier Social Stress Test (TSST) before and after the biological measures, including BDNF, and cortisol levels were obtained. Results: After the TSST, Cohen's d values between CUD-primary-MDD and CUD-induced-MDD increased in each assessment from 0.19 post-TSST to 2.04 post-90-TSST. Pairwise differences among CUD-induced-MDD and both MDD and HC groups had also a large effect size value in post-30-TSST and post-90-TSST. In the case of the BDNF concentrations, CUD-primary-MDD and CUD-induced-MDD in post-90-TSST (12,627.27 ± 5488.09 vs.17,144.84 ± 6581.06, respectively) had a large effect size (0.77). Conclusion: Results suggest a different pathogenesis for CUD-induced-MDD with higher levels of cortisol and BDNF compared with CUD-primary-MDD. Such variations should imply different approaches in treatment.
  • dc.description.sponsorship This work was supported by grants from the Instituto de Salud Carlos III–ISCIII Red de Trastornos Adictivos 2016 (RD16/0017/0010 and RD16/0017/0003); Fondo de Investigación Sanitaria (FIS) (PI09/02121, PI12/01838, PI16/00603); National R + D+I and funded by the Instituto de Salud Carlos III (ISCIII) and the European Regional Development Fund (FEDER) grant Juan Rodes (JR 16/00020); Ministerio de Sanidad, Política Social e Igualdad, Plan Nacional Sobre Drogas (PNSD) (2012I054); Suport Grups de Recerca AGAUR-Gencat (2017 SGR 316, 2017 SGR 530); Ministerio de Economía y Competitividad (MTM2015-64465-C2-1-R); ISCIII-Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS); Red de Investigación en Atención Primaria de Adicciones (RIAPAd), grant number RD21/0009/0001. The funding agencies had no role in study design, data collection, interpretation, and no influence on the writing.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Fonseca F, Mestre-Pinto JI, Rodríguez-Minguela R, Papaseit E, Pérez-Mañá C, Langohr K, Barbuti M, Farré M, Torrens M; NEURODEP GROUP. BDNF and cortisol in the diagnosis of cocaine-induced depression. Front Psychiatry. 2022 Mar 15;13:836771. DOI: 10.3389/fpsyt.2022.836771
  • dc.identifier.doi http://dx.doi.org/10.3389/fpsyt.2022.836771
  • dc.identifier.issn 1664-0640
  • dc.identifier.uri http://hdl.handle.net/10230/54115
  • dc.language.iso eng
  • dc.publisher Frontiers
  • dc.relation.ispartof Front Psychiatry. 2022 Mar 15;13:836771
  • dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/MTM2015-64465-C2-1-R
  • dc.rights © 2022 Fonseca, Mestre-Pinto, Rodríguez-Minguela, Papaseit, Pérez-Mañá, Langohr, Barbuti, Farré, Torrens and NEURODEP GROUP. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by/4.0/
  • dc.subject.keyword Brain derived neurotrophic factor (BDNF)
  • dc.subject.keyword Cocaine use disorder
  • dc.subject.keyword Cortisol
  • dc.subject.keyword Depression
  • dc.subject.keyword Dual diagnosis
  • dc.title BDNF and cortisol in the diagnosis of cocaine-induced depression
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)
Articles (Departament de Medicina i Ciències de la Vida)